



United in the Prevention of Bacterial Resistance during the Post-pandemic Era

Guest Editors:

Dr. Simin-Aysel Florescu

Department of Infectious Diseases, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania

Dr. Simona Claudia Cambrea

Head of Infectious Disease Clinic, Faculty of Medicine, "Ovidius" University, 900470 Constanta, Romania

Deadline for manuscript submissions:

20 December 2024

Message from the Guest Editors

Antimicrobial resistance (AMR) is inducing an increasingly significant burden on public health, with this issue becoming even more pronounced in the context of COVID-19 pandemic. Infections with SARS-CoV-2, until recently an absolutely unknown element in the landscape of infectious pathology. And a systematic, early, and often non-judicious administration of antibiotics has been observed, even in the absence of any data attesting to a co-infection. An eventual later development of a true superinfection often necessitated therapy escalation or an extension of the administration period of the initial antibiotic regimen.

Last but not least, the dramatic increase in the misuse or overuse of reserve antibiotics is worrisome, with difficult-to-quantify consequences concerning the resistance patterns of certain germs or the mortality rates associated with these infections.

This Special Issue aims to provide an appropriate platform for the sharing of experiences gained during the COVID-19 pandemic period. Therefore, original research and reviews from interdisciplinary areas focusing on antibiotic therapy and antibiotic resistance related to COVID-19 will be of great interest.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi